The Experts below are selected from a list of 13026 Experts worldwide ranked by ideXlab platform

Alison Reid - One of the best experts on this subject based on the ideXlab platform.

  • molecular characterisation of erg etv1 and PTEN Gene loci identifies patients at low and high risk of death from prostate cancer
    British Journal of Cancer, 2010
    Co-Authors: Gerhardt Attard, Gabrielle Fisher, Alison Reid, Daniel Brewer, Gyula Kovacs, Jeremy Clark, Laurence Ambroisine, Penny Flohr
    Abstract:

    BACKGROUND: The discovery of ERG/ETV1 Gene rearrangements and PTEN Gene loss warrants investigation in a mechanism-based prognostic classification of prostate cancer (PCa). The study objective was to evaluate the potential clinical significance and natural history of different disease categories by combining ERG/ETV1 Gene rearrangements and PTEN Gene loss status. METHODS: We utilised fluorescence in situ hybridisation (FISH) assays to detect PTEN Gene loss and ERG/ETV1 Gene rearrangements in 308 conservatively managed PCa patients with survival outcome data. RESULTS: ERG/ETV1 Gene rearrangements alone and PTEN Gene loss alone both failed to show a link to survival in multivariate analyses. However, there was a strong interaction between ERG/ETV1 Gene rearrangements and PTEN Gene loss (Po0.001). The largest subgroup of patients (54%), lacking both PTEN Gene loss and ERG/ETV1 Gene rearrangements comprised a ‘good prognosis’ population exhibiting favourable cancer-specific survival (85.5% alive at 11 years). The presence of PTEN Gene loss in the absence of ERG/ETV1 Gene rearrangements identified a patient population (6%) with poorer cancer-specific survival that was highly significant (HR ¼4.87, Po0.001 in multivariate analysis, 13.7% survival at 11 years) when compared with the ‘good prognosis’ group. ERG/ETV1 Gene rearrangements and PTEN Gene loss status should now prospectively be incorporated into a predictive model to establish whether predictive performance is improved. CONCLUSIONS: Our data suggest that FISH studies of PTEN Gene loss and ERG/ETV1 Gene rearrangements could be pursued for patient stratification, selection and hypothesis-Generating subgroup analyses in future PCa clinical trials and potentially in patient management.

Yusuke Nakamura - One of the best experts on this subject based on the ideXlab platform.

  • growth suppression of human ovarian cancer cells by adenovirus mediated transfer of the PTEN Gene
    Cancer Research, 1999
    Co-Authors: Takeo Minaguchi, Toshiki Mori, Yasunobu Kanamori, Mieko Matsushima, Hiroyuki Yoshikawa, Yuji Taketani, Yusuke Nakamura
    Abstract:

    A tumor suppressor Gene on chromosome 10q23, PTEN , encodes a phosphatidylinositol phosphatase that antagonizes activation of the phosphatidylinositol 3′-kinase-mediated pathway involved in cell growth. A Gene encoding the catalytic subunit of phosphatidylinositol 3′-kinase ( PIK3CA ) is frequently activated in ovarian cancers; therefore, overexpression of the PTEN product through Gene transfer might be an effective strategy for treating ovarian cancers. To test the potential for this type of Gene therapy, we constructed a recombinant adenovirus encoding wild-type PTEN and examined its effects on nine cell lines derived from human ovarian carcinomas. Transduction of the PTEN Gene significantly inhibited growth of six of these cell lines compared with infection with virus alone, and the degree of inhibition correlated with the efficiency of Gene transfer as determined by β-galactosidase assay. Results of flow cytometry suggested that the observed effects were mediated by two mechanisms, apoptosis and/or arrest in the G1 phase of the cell cycle, and that high adenoviral transduction efficiency of cells was associated with induction of apoptosis. We also found that the level of transcription of Integrin αv in ovarian cancer cells correlated with the efficiency of transduction ( P = 0.014) and with the degree of growth inhibition after PTEN Gene transfer ( P = 0.009). These findings carry significant implications for adenovirus vector-based PTEN Gene therapies for ovarian cancers.

Jing Zhang - One of the best experts on this subject based on the ideXlab platform.

  • Clinical significance of PTEN Gene promoter methylation in triple-negative breast cancer
    Tumori, 2016
    Co-Authors: Jie Zhang, Feng-hua Zhang, Tian Yao, Shuai Yang, Li Qin, Yu-zhe Zhao, Jing Zhang
    Abstract:

    Objective: To detect the methylation status of phosphatase and tensin homology deleted on chromosome ten (PTEN) Gene promoter in triple-negative breast cancer, and to analyze the correlation of PTEN Gene methylation with the clinical and pathological characteristics of breast cancer patients. Methods: All of sixty cases of triple-negative breast cancer tissue specimens and sixteen cases of fresh normal breast tissue specimens (as the control) were selected. The methylation rate of PTEN Gene promoter in the two groups was detected by pyrophosphate sequencing method. The expression levels of Ki-67, E-cadherin, vascular endothelial growth factor (VEGF), p53, and epidermal growth factor receptor (EGFR) were determined by immunohistochemical method. Then the relationships of PTEN Gene methylation rate and the different clinical and pathological parameters of patients with triple-negative breast cancer were statistically analyzed. Results: The methylation rate of PTEN Gene promoter in triple-negative breast cancer tissues was significantly higher than that in normal breast tissues (P < 0.05). For the patients with triple-negative breast cancer, the methylation rate of PTEN Gene in cancer tissues at stage Ⅲ was higher than that at stage 0-Ⅱ (P < 0.01), the one with lymph node metastasis was higher than that without lymph node metastasis (P < 0.01). Moreover, the methylation rates of PTEN Gene in triple-negative breast cancer tissues with medium and high expressions of VEGF and p53 were higher than those with negative and low expressions of VEGF and p53 (both P < 0.01), and the one with Ki-67 level ≥ 14 % was higher than that with Ki-67 < 14 % (P < 0.01). Conclusion: The methylation status of PTEN Gene promoter in triple-negative breast cancer tissues may be related with the clinical stage, lymph node metastasis and the expressions of VEGF, p53 and Ki-67 proteins, suggesting that PTEN Gene methylation may play an important role in the occurrence and development of triple-negative breast cancer. DOI:10.3781/j.issn.1000-7431.2016.33.466

Penny Flohr - One of the best experts on this subject based on the ideXlab platform.

  • molecular characterisation of erg etv1 and PTEN Gene loci identifies patients at low and high risk of death from prostate cancer
    British Journal of Cancer, 2010
    Co-Authors: Gerhardt Attard, Gabrielle Fisher, Alison Reid, Daniel Brewer, Gyula Kovacs, Jeremy Clark, Laurence Ambroisine, Penny Flohr
    Abstract:

    BACKGROUND: The discovery of ERG/ETV1 Gene rearrangements and PTEN Gene loss warrants investigation in a mechanism-based prognostic classification of prostate cancer (PCa). The study objective was to evaluate the potential clinical significance and natural history of different disease categories by combining ERG/ETV1 Gene rearrangements and PTEN Gene loss status. METHODS: We utilised fluorescence in situ hybridisation (FISH) assays to detect PTEN Gene loss and ERG/ETV1 Gene rearrangements in 308 conservatively managed PCa patients with survival outcome data. RESULTS: ERG/ETV1 Gene rearrangements alone and PTEN Gene loss alone both failed to show a link to survival in multivariate analyses. However, there was a strong interaction between ERG/ETV1 Gene rearrangements and PTEN Gene loss (Po0.001). The largest subgroup of patients (54%), lacking both PTEN Gene loss and ERG/ETV1 Gene rearrangements comprised a ‘good prognosis’ population exhibiting favourable cancer-specific survival (85.5% alive at 11 years). The presence of PTEN Gene loss in the absence of ERG/ETV1 Gene rearrangements identified a patient population (6%) with poorer cancer-specific survival that was highly significant (HR ¼4.87, Po0.001 in multivariate analysis, 13.7% survival at 11 years) when compared with the ‘good prognosis’ group. ERG/ETV1 Gene rearrangements and PTEN Gene loss status should now prospectively be incorporated into a predictive model to establish whether predictive performance is improved. CONCLUSIONS: Our data suggest that FISH studies of PTEN Gene loss and ERG/ETV1 Gene rearrangements could be pursued for patient stratification, selection and hypothesis-Generating subgroup analyses in future PCa clinical trials and potentially in patient management.

Akbar Pejhan - One of the best experts on this subject based on the ideXlab platform.

  • Prognostic Role of PTEN Gene Expression and Length of Survival of Breast Cancer Patients in the North East of Iran.
    Asian Pacific Journal of Cancer Prevention, 2016
    Co-Authors: Rahim Golmohammadi, Mohammad Hassan Rakhshani, Alireza Moslem, Akbar Pejhan
    Abstract:

    Abstract PTEN protein is an important tumour suppressor factor detectable by immunohistochemistry. The goal of the present study was to investigate the prognostic role of PTEN Gene expression focusing on length of survival in breast cancer patients. This descriptive-analytical study was conducted on 100 breast cancer cases referred to Sabzevar hospitals in the north east of Iran between 2010 and 2011, followed up to 2015. The PTEN Gene expression of tumour tissue samples was determined using specific monoclonal antibodies. The data were analyzed using Chi-square test and Fisher's exact test. Patient length of survival was analyzed after 4 years of follow-up using the Cox regression model. The PTEN Gene was expressed in 70 of 100 samples, while being found at a high level in all noncancerous samples. There was an inverse significant relationship between expression of PTEN and tumour stage and grade (p

  • Prognostic Role of PTEN Gene Expression in Breast Cancer Patients from North-East Iran
    Asian Pacific Journal of Cancer Prevention, 2016
    Co-Authors: Rahim Golmohammadi, Mohammad Hassan Rakhshani, Alireza Moslem, Akbar Pejhan
    Abstract:

    Background: PTEN protein is one of the most important tumour suppressor factors which is detectable by immunohistochemistry. The goal of the present study was to investigate the prognostic role of PTEN Gene expression in breast cancer patients. Materials and Methods: This descriptive-analytical study was conducted on 100 breast cancer patients referred to Sabzevar hospitals in the north-east of Iran between 2010 and 2011, who were followed up to 2015. PTEN Gene expression in tissue samples was determined using specific monoclonal antibodies and data were analyzed using Chi-square test and Fisher’s exact test. Patient survival was analyzed after 4 years of follow-up using the Cox regression model. Results: PTEN Gene expression was evident in 70 of 100 cnacer samples but was found at high levels in all non-cancer samples. There was an inverse significant relationship between PTEN Gene expression and tumour stage or tumour grade (p